Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?-Reference-Cited by-同舟云学术

Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Siopi Maria¹,Perlin David S.²,Arendrup Maiken C.³⁴⁵^ORCID,Pournaras Spyros¹,Meletiadis Joseph¹^ORCID

Affiliation:

1. Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

2. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

3. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark

4. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

5. Department of Clinical Microbiology, University of Copenhagen, Copenhagen, Denmark

Abstract

Echinocandins have been used as primary therapy of invasive aspergillosis (IA), with suboptimal results at standard dosing. Here, we explored the efficacy of dose escalation in a validated in vitro pharmacokinetic/pharmacodynamic (PK/PD) model.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01618-20

Reference60 articles.

1. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

2. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

3. Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside

4. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasiveAspergillusinfections

5. Micafungin for the treatment of invasive aspergillosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?;Journal of Fungi;2024-03-14

2. Aspergillus fumigatus escape mechanisms from its harsh survival environments;Applied Microbiology and Biotechnology;2024-01-04

3. Optimization of the EUCAST reference broth microdilution method for echinocandin susceptibility testing of Aspergillus fumigatus;Journal of Antimicrobial Chemotherapy;2023-10-09

4. Breakthrough Acute Necrotizing Invasive Fungal Rhinosinusitis by Alternariaalternata in a Patient with Acute Lymphoblastic Leukemia on Anidulafungin Therapy and Case-Based Literature Review;Journal of Fungi;2022-08-20

5. Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?;Antibiotics;2022-05-12